These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 36901973)
1. Protein Abundance of Drug Metabolizing Enzymes in Human Hepatitis C Livers. Drozdzik M; Lapczuk-Romanska J; Wenzel C; Skalski L; Szeląg-Pieniek S; Post M; Parus A; Syczewska M; Kurzawski M; Oswald S Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901973 [TBL] [Abstract][Full Text] [Related]
2. Gene Expression and Protein Abundance of Hepatic Drug Metabolizing Enzymes in Liver Pathology. Drozdzik M; Lapczuk-Romanska J; Wenzel C; Szelag-Pieniek S; Post M; Skalski Ł; Kurzawski M; Oswald S Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575411 [TBL] [Abstract][Full Text] [Related]
3. Interaction between Changan Granule and its main components in the plasma and CYP450 enzymes. Liu X; Wang Q; Chen M; Tao J; Wang J; Liu S; Hou J; Li D; Wang R J Ethnopharmacol; 2023 May; 308():116303. PubMed ID: 36841379 [TBL] [Abstract][Full Text] [Related]
4. Characterisation of cytochrome P450 isoenzyme activity in sheep liver and placental microsomes. Meakin AS; Amirmostofian M; Darby JR; Holman SL; Morrison JL; Wiese MD Placenta; 2023 Jan; 131():82-89. PubMed ID: 36527743 [TBL] [Abstract][Full Text] [Related]
5. Traditional Herbal Formulas to as Treatments for Musculoskeletal Disorders: Their Inhibitory Effects on the Activities of Human Microsomal Cytochrome P450s and UDP-glucuronosyltransferases. Jin SE; Seo CS; Shin HK; Ha H Pharmacogn Mag; 2016; 12(48):241-252. PubMed ID: 27867264 [TBL] [Abstract][Full Text] [Related]
6. The reference liver-CYP450 and UGT enzymes in healthy donor and metastatic livers: the impact of genotype. Kurzawski M; Szeląg-Pieniek S; Łapczuk-Romańska J; Wrzesiński M; Oswald S; Droździk M Pharmacol Rep; 2022 Feb; 74(1):204-215. PubMed ID: 34741761 [TBL] [Abstract][Full Text] [Related]
7. Mass spectrometry-based targeted proteomics method for the quantification of clinically relevant drug metabolizing enzymes in human specimens. Wenzel C; Drozdzik M; Oswald S J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1180():122891. PubMed ID: 34390906 [TBL] [Abstract][Full Text] [Related]
8. Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study. Prasad B; Bhatt DK; Johnson K; Chapa R; Chu X; Salphati L; Xiao G; Lee C; Hop CECA; Mathias A; Lai Y; Liao M; Humphreys WG; Kumer SC; Unadkat JD Drug Metab Dispos; 2018 Jul; 46(7):943-952. PubMed ID: 29695616 [TBL] [Abstract][Full Text] [Related]
9. The Effects of AT-533 and AT-533 gel on Liver Cytochrome P450 Enzymes in Rats. Wu Y; Li M; Guo Y; Liu T; Zhong L; Huang C; Ye C; Liu Q; Ren Z; Wang Y Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):345-352. PubMed ID: 35137361 [TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro. He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485 [TBL] [Abstract][Full Text] [Related]
11. Postmortem protein stability investigations of the human hepatic drug-metabolizing cytochrome P450 enzymes CYP1A2 and CYP3A4 using mass spectrometry. Hansen J; Palmfeldt J; Pedersen KW; Funder AD; Frost L; Hasselstrøm JB; Jornil JR J Proteomics; 2019 Mar; 194():125-131. PubMed ID: 30529742 [TBL] [Abstract][Full Text] [Related]
12. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma. Zhou J; Wen Q; Li SF; Zhang YF; Gao N; Tian X; Fang Y; Gao J; Cui MZ; He XP; Jia LJ; Jin H; Qiao HL Oncotarget; 2016 Aug; 7(31):50612-50623. PubMed ID: 27203676 [TBL] [Abstract][Full Text] [Related]
13. In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions. Wójcikowski J; Danek PJ; Basińska-Ziobroń A; Pukło R; Daniel WA Pharmacol Rep; 2020 Jun; 72(3):612-621. PubMed ID: 32219694 [TBL] [Abstract][Full Text] [Related]
14. Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies. Mazzarino M; Biava M; de la Torre X; Fiacco I; Botrè F Anal Bioanal Chem; 2013 Jun; 405(16):5467-87. PubMed ID: 23604525 [TBL] [Abstract][Full Text] [Related]
15. Protein Abundance of Drug Transporters in Human Hepatitis C Livers. Droździk M; Lapczuk-Romanska J; Wenzel C; Skalski Ł; Szeląg-Pieniek S; Post M; Syczewska M; Kurzawski M; Oswald S Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887291 [TBL] [Abstract][Full Text] [Related]
16. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470 [TBL] [Abstract][Full Text] [Related]
17. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms. Renwick AB; Surry D; Price RJ; Lake BG; Evans DC Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104 [TBL] [Abstract][Full Text] [Related]
18. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661 [TBL] [Abstract][Full Text] [Related]
19. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Rifkind AB; Lee C; Chang TK; Waxman DJ Arch Biochem Biophys; 1995 Jul; 320(2):380-9. PubMed ID: 7625847 [TBL] [Abstract][Full Text] [Related]
20. An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point. Youdim KA; Lyons R; Payne L; Jones BC; Saunders K J Pharm Biomed Anal; 2008 Sep; 48(1):92-9. PubMed ID: 18584988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]